PolyTherics and Spirogen Ltd. Announce a Research Collaboration to Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

Published: Apr 02, 2012

LONDON--(BUSINESS WIRE)--PolyTherics Limited (“PolyTherics”), a provider of solutions to enable the development of better biopharmaceuticals, and Spirogen Limited ("Spirogen"), a leading oncology-focused company developing DNA sequence-targeted agents, announce that they have formed a research collaboration to develop antibody drug conjugates (ADCs) that combine PolyTherics’ proprietary site-specific conjugation chemistry with Spirogen’s highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.

Back to news